Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery

Thrombosis and Haemostasis

Volumn 80, Issue 5, 1998, Pages 773-778

  Shapiro, Amy D ^a,e   Gilchrist, Gerald S ^b   Hoots, W Keith ^c   Cooper, Herbert A ^d   Gastineau, Dennis A ^b  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^e Indiana Hemophilia Thromb Ctr Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ELECTIVE SURGERY; HEMOPHILIA; HEMOSTASIS; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WOUND CLOSURE;

EID: 0031743504     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615357     Document Type: Article

References (25)

1. Macik BG. Treatment of factor VIII inhibitors: products and strategies. Semen Thromb Hemost 1993; 19: 13-24.
2. Nilsson IM, Berntop E, Freiburghaus C. Treatment of patients with Factor VIII and IX inhibitors. Thromb Haemost 1993; 70: 56-9.
3. Bray G, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White G III, Lee M. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy and inhibitor risk in previously untreated patients with haemophilia A. The Recombinate Study Group. Blood 1994; 83: 2428-35.
4. Brettler DB, Forsberg MS, Levine PH, Aledort LM, Hiltgartner MW, Kasper CK, Lusher JM, McMillan C, Roberts H, on behalf of the Cooperating Investigators. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience. Arch Intern Med 1989; 149: 1381-5.
5. Hay CRM, Lozier JN, Lee CA, Tradati H, Santagostino E, Ciavarella N, Schiavoni M, Fukiu H, Yoskioka A. Porcine factor VIII in patients with congenital hemophilia and inhibitors: efficacy, patient selection and side effects. Semin Hematol 1994; 31: 20-5.
6. Lusher JM. Use of prothrombin complex concentrates in management of bleeding in hemophiliacs with inhibitors - benefits and limitations. Semin Hematol 1994; 31: 49-52.
7. Rao LVM, Rapaport SI. Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of coagulation. Proc Natl Acad Sci USA 1988; 85: 6687-91.
8. Brinkhous KM, Hedner U, Garris JB, Diness V, Read MS. Effect of recombinant factor Vila on the hemostatic defect in dogs with hemophilia A. hemophilia B. and von Willebrand disease. Proc Natl Acad Sci USA 1989; 86: 1382-6.
9. Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird-Cox K, Birch K, Glazer S, Roberts HR. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 638-48.
10. Hedner U, Glazer S. Management of hemophilia patients with inhibitors. Hematol Oncol Clin North Am 1992; 6: 1035-46.
11. Roberts H. Clinical experience with recombinant factor Vila (Novo Seven®): summary of efficacy and safety. Haemophilia 1996; 2: 63.
12. Lusher JM. Recombinant factor VIIa (NovoSeven®) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. Haemostasis 1996; 26: 124-30.
13. Rice KM, Savidge GF, NovoSeven® (Recombinant factor VIIa) in central nervous system bleeds. Haemost 1996; 26: 131-4.
14. Mølskov Bech R. Recombinant factor VIIa in joint and muscle bleeding episodes. Haemostasis 1996; 26: 135-8.
15. Nicolaisen EM, Hansen LL, Poulsen F, Glazer S, Hedner U. Immunological aspects of recombinant factor Vila (rFVIIa) in clinical use. Thromb Haemost 1996; 76: 200-4.
16. Hedner U, Glazer S, Pingel K, Alberts KA, Blomback M, Schulman S, Johnsson H. Successful use of recombinant factor VIIa in patients with severe haemophilia A during synovectomy. Lancet 1988; ii: 1193.
17. Ingerslev J, Freidman D, Gastineau D, Gilchrist G, Johnsson H, Lucas G, McPherson JJ, Preston E, Scheibel E, Shuman M. Major surgery in haemophiliac patients with inhibitors using recombinant factor VIIa. Haemostasis 1996; 26: 118-23.
18. O'Marcaigh AS, Schmalz BJ, Shaughnessy WJ, Gilchrist GS. Successful hemostasis during a major orthopedic operation by using recombinant activated factor VII in a patient with severe hemophilia A and a potent inhibitor. Mayo Clin Proc 1994; 69: 641-4.
19. Schulman S, Bech Jensen M, Varon D, Keller N, Gitel S, Horoszowski H, Heim M, Martinowitz U. Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost 1996; 75: 432-6.
20. Egan EL, Bowie EJW, Kazmier FJ, Gilchrist GS, Woods JW, Owen CA Jr. Effect of surgical operations on certain tests used to diagnose intravascular coagulation and fibrinolysis. Mayo Clin Proc 1974; 49: 658-64.
21. Gaffney PJ, Creighton LJ, Callus M, Thorpe R. Monoclonal antibodies to crosslinked fibrin degradation products (XL-FDP). II. Evaluation in a variety of clinical conditions. Br J Haematol 1988; 68: 91-6.
22. Van Wersch JW, de Vries-Hanje JC, Oosterbos C. Coagulation activation and reactive fibrinolysis in patients receiving oral anticoagulation after total hip or knee replacement. Blood Coag Fibrinol 1994; 5: 604-8.
23. Schmidt ML, Gamerman S, Smith HE, Scott JP, DiMichele DM. Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors. Am J Hematol 1994; 47: 36-40.
24. Glazer S, Hedner U, Falch JF. Clinical update on the use of recombinant factor Vila. Proceedings of the 2nd International Symposium on inhibitors to coagulation factors. Aledort LM, White GC, eds. New York: Plenum Publishing Corp 1993; 163-74.
25. Bell BA, Birch K, Glazer S. Experience with recombinant factor VIIa in an infant hemophilia with inhibitors to FVII:C undergoing emergency central line placement. Am J Pediatr Hematol Oncol 1993; 15: 77-9.